{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:00:09Z","timestamp":1793505609607,"version":"4.5.0"},"reference-count":123,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Peritoneal cancer (PC) is a dire finding, yet in selected patients, long-term survival is possible. Complete cytoreductive surgery (CRS) together with combination immunochemotherapy is essential to achieve cure. Hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC) are increasingly added to the multimodal treatment. The Swiss Peritoneal Cancer Group (SPCG) is an interdisciplinary group of expert clinicians. It has developed comprehensive treatment algorithms for patients with PC from pseudomyxoma peritonei, peritoneal mesothelioma, gastric, and colorectal origin. They include multimodal neoadjuvant treatment, surgical resection, and palliative care. The indication for and results of CRS HIPEC and PIPAC are discussed in light of the current literature. Institutional volume and clinical expertise required to achieve best outcomes are underlined, while inclusion of patients considered for CRS HIPEC and PIPAC in a clinical registry is strongly advised. The present recommendations are in line with current international guidelines and provide the first comprehensive treatment proposal for patients with PC including intraperitoneal chemotherapy. The SPCG comprehensive treatment algorithms provide evidence-based guidance for the multimodal care of patients with PC of gastrointestinal origin that were endorsed by all Swiss clinicians routinely involved in the multimodal care of these challenging patients.<\/jats:p>","DOI":"10.3390\/cancers14174275","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T21:27:17Z","timestamp":1662067637000},"page":"4275","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-6953","authenticated-orcid":false,"given":"Michel","family":"Adamina","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Viszeral- und Thoraxchirurgie, Kantonsspital Winterthur, 8401 Winterthur, Switzerland"},{"name":"Faculty of Medicine, University of Basel, 4056 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0025-2817","authenticated-orcid":false,"given":"Maxime","family":"Warlaumont","sequence":"additional","affiliation":[{"name":"Chirurgie Digestive et Canc\u00e9rologique, CHU de Lille, CH de Cambrai, 59000 Lille, France"},{"name":"Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"D\u00e4ster","sequence":"additional","affiliation":[{"name":"Clarunis, Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, St. Claraspital and University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Delaloye","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7189-3035","authenticated-orcid":false,"given":"Antonia","family":"Digklia","sequence":"additional","affiliation":[{"name":"Department of Oncology, Lausanne University Hospital CHUV, University of Lausanne, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Gloor","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery and Medicine, Inselspital, University Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Fritsch","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Koeberle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, St. Claraspital, 4002 Basel, Switzerland"},{"name":"Faculty of Medicine, University of Bern, 3012 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9196-9076","authenticated-orcid":false,"given":"Thibaud","family":"Koessler","sequence":"additional","affiliation":[{"name":"Department of Oncology, Geneva University Hospital, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuno","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Department of Surgery and Transplantation, University Hospital Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phaedra","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Viszeral- und Thoraxchirurgie, Kantonsspital Winterthur, 8401 Winterthur, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0038-9795","authenticated-orcid":false,"given":"Ralph","family":"Peterli","sequence":"additional","affiliation":[{"name":"Clarunis, Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, St. Claraspital and University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7421-6101","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Ris","sequence":"additional","affiliation":[{"name":"Division of Digestive Surgery, University Hospitals of Geneva, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9374-5703","authenticated-orcid":false,"given":"Thomas","family":"Steffen","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Allgemein-, Viszeral-, Endokrine und Transplantationschirurgie, Kantonsspital St. Gallen, 9000 St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Stefan","family":"Weisshaupt","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Kantonsspital St. Gallen, 9000 St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-8279","authenticated-orcid":false,"given":"Martin","family":"H\u00fcbner","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","article-title":"Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of north central cancer treatment group phase III trials N9741 and N9841","volume":"30","author":"Franko","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/ijc.25596","article-title":"Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population-based study","volume":"128","author":"Lemmens","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1245\/s10434-016-5686-1","article-title":"Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases","volume":"24","author":"Garofalo","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1290 patients","volume":"116","author":"Glehen","year":"2010","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejso.2010.01.006","article-title":"Pseudomyxoma peritonei: A French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy","volume":"36","author":"Elias","year":"2010","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer"},{"key":"ref_8","unstructured":"American Cancer Society (2022, July 18). Cancer Facts & Figures. Available online: http:\/\/www.cancer.org."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br. J. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejso.2020.02.012","article-title":"Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment","volume":"47","author":"Govaerts","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejso.2020.02.011","article-title":"Peritoneal mesothelioma: PSOGI\/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"47","author":"Kusamura","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/02656736.2021.1903585","article-title":"Multicystic peritoneal mesothelioma treated with cytoreductive surgery followed or not by hyperthermic intraperitoneal chemotherapy: Results from a large multicentric cohort","volume":"38","author":"Kepenekian","year":"2021","journal-title":"Int. J. Hyperth."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"zraa001","DOI":"10.1093\/bjsopen\/zraa001","article-title":"Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"5","author":"Zahid","year":"2021","journal-title":"BJS Open"},{"key":"ref_15","first-page":"391","article-title":"Ten-year experience with peritoneal mesothelioma","volume":"24","author":"Kyziridis","year":"2019","journal-title":"J. Buon."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chicago Consensus Working Group (2020). The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma. Cancer, 126, 2547\u20132552.","DOI":"10.1002\/cncr.32870"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/jso.23722","article-title":"American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer","volume":"110","author":"Esquivel","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","article-title":"Intraperitoneal chemotherapy for peritoneal surface malignancy: Experience with 1,000 patients","volume":"218","author":"Levine","year":"2014","journal-title":"J. Am. Coll. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e206363","DOI":"10.1001\/jamasurg.2020.6363","article-title":"The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery","volume":"156","author":"Kusamura","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_20","first-page":"72","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: Survival outcomes and patient selection","volume":"7","author":"Esquivel","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Quenet","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1245\/s10434-008-0127-4","article-title":"Peritoneal surface disease from colorectal cancer: Comparison with the hepatic metastases surgical paradigm in optimally resected patients","volume":"15","author":"Shen","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","article-title":"Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin","volume":"27","author":"Elias","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study","volume":"22","author":"Glehen","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1245\/s10434-021-10157-0","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of \u2018Italian Peritoneal Surface Malignancies Oncoteam-S.I.C.O.\u2019","volume":"28","author":"Marano","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1016\/j.ejso.2021.05.016","article-title":"Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials","volume":"47","author":"Granieri","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1245\/s10434-019-07425-5","article-title":"Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma","volume":"27","author":"Ali","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1245\/s10434-012-2579-9","article-title":"Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Is it worth the risk?","volume":"20","author":"Tsilimparis","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1245\/s10434-013-3133-0","article-title":"Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An Asian perspective","volume":"20","author":"Tan","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1245\/s10434-020-08443-4","article-title":"Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Early Results from a Prospective Cohort Study of 115 Patients","volume":"27","author":"Steffens","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejso.2019.05.006","article-title":"Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer","volume":"47","author":"Koole","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1245\/s10434-016-5547-y","article-title":"Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy","volume":"23","author":"Dodson","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1245\/s10434-019-08064-6","article-title":"Health-Related Quality of Life After Cytoreductive Surgery\/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin","volume":"27","author":"Moaven","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/bjs.10521","article-title":"Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis","volume":"104","author":"Grass","year":"2017","journal-title":"Br. J. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2015.02.009","article-title":"Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study","volume":"137","author":"Tempfer","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis","volume":"20","author":"Nadiradze","year":"2016","journal-title":"J. Gastrointest. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/codi.13130","article-title":"Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis","volume":"18","author":"Demtroder","year":"2016","journal-title":"Colorectal. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.ejso.2015.06.001","article-title":"Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)","volume":"41","author":"Odendahl","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6852749","DOI":"10.1155\/2017\/6852749","article-title":"Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Retrospective Cohort Study","volume":"2017","author":"Hubner","year":"2017","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_42","first-page":"4596176","article-title":"Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study","volume":"2017","author":"Grass","year":"2017","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/DCR.0000000000001565","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy, a Palliative Treatment Approach for Patients with Peritoneal Carcinomatosis: Description of Method and Systematic Review of Literature","volume":"63","author":"Winkler","year":"2020","journal-title":"Dis. Colon Rectum."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/his.13829","article-title":"Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis","volume":"74","author":"Solass","year":"2019","journal-title":"Histopathology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Schmucker, C.M., Blumle, A., Schell, L.K., Schwarzer, G., Oeller, P., Cabrera, L., von Elm, E., Briel, M., Meerpohl, J.J., and on behalf of the OPEN Consortium (2017). Systematic review finds that study data not published in full text articles have unclear impact on meta-analyses results in medical research. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176210"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/02656736.2017.1310938","article-title":"Pseudomyxoma peritonei: Natural history and treatment","volume":"33","author":"Mittal","year":"2017","journal-title":"Int. J. Hyperth."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13023-021-01723-6","article-title":"Consensuses and controversies on pseudomyxoma peritonei: A review of the published consensus statements and guidelines","volume":"16","author":"Lin","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejso.2007.04.002","article-title":"Appendiceal neoplasms and pseudomyxoma peritonei: A population based study","volume":"34","author":"Smeenk","year":"2008","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/bjs.10716","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin","volume":"105","author":"Delhorme","year":"2018","journal-title":"Br. J. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/bjs5.97","article-title":"Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"3","author":"Mercier","year":"2019","journal-title":"BJS Open"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/codi.15778","article-title":"Appendiceal pseudomyxoma peritonei: Predictors of recurrence and iterative surgery","volume":"23","author":"Kong","year":"2021","journal-title":"Colorectal. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ejso.2014.08.476","article-title":"Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours","volume":"41","author":"Lord","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12957-016-0804-x","article-title":"Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis","volume":"14","author":"Vassos","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Chicago Consensus Working Group (2020). The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. Cancer, 126, 2525\u20132533.","DOI":"10.1002\/cncr.32881"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","article-title":"A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process","volume":"40","author":"Carr","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ejso.2019.05.007","article-title":"Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: A multicenter study","volume":"45","author":"Sgarbura","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2743985","DOI":"10.1155\/2018\/2743985","article-title":"Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study","volume":"2018","author":"Kurtz","year":"2018","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canep.2017.10.008","article-title":"Epidemiology of malignant peritoneal mesothelioma: A population-based study","volume":"51","author":"Salo","year":"2017","journal-title":"Cancer Epidemiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdl345","article-title":"Epidemiology of peritoneal mesothelioma: A review","volume":"18","author":"Boffetta","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kitadai, R., Shimoi, T., Sudo, K., Noguchi, E., Nagata, Y., Sawada, R., Takashima, A., Boku, N., and Yonemori, K. (2021). Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: A retrospective study. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08025-x"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12957-016-1008-0","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"14","author":"Girshally","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","article-title":"Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: An innovative approach to treat peritoneal carcinomatosis","volume":"14","author":"Robella","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejso.2019.06.028","article-title":"Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"47","author":"Alyami","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.ejso.2017.09.010","article-title":"Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis","volume":"43","author":"Alyami","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Giger-Pabst, U., Demtroder, C., Falkenstein, T.A., Ouaissi, M., Gotze, T.O., Rezniczek, G.A., and Tempfer, C.B. (2018). Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4363-0"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/annonc\/mdz180","article-title":"Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer","volume":"30","author":"Pentheroudakis","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_69","first-page":"912418","article-title":"The treatment of peritoneal carcinomatosis in advanced gastric cancer: State of the art","volume":"2014","author":"Montori","year":"2014","journal-title":"Int. J. Surg. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Seyfried, F., von Rahden, B.H., Miras, A.D., Gasser, M., Maeder, U., Kunzmann, V., Germer, C.T., Pelz, J., and Kerscher, A.G. (2015). Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin\u2014A longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1081-8"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/gutjnl-2018-318070","article-title":"Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response","volume":"69","author":"Wang","year":"2020","journal-title":"Gut"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"864647","DOI":"10.3389\/fonc.2022.864647","article-title":"Gastric Cancer with Peritoneal Metastasis\u2014A Comprehensive Review of Current Intraperitoneal Treatment Modalities","volume":"12","author":"Prabhu","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.suronc.2020.05.006","article-title":"Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis","volume":"34","author":"Schena","year":"2020","journal-title":"Surg. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9","article-title":"Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma","volume":"85","author":"Fujimoto","year":"1999","journal-title":"Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/bjs\/znab200","article-title":"Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study)","volume":"108","author":"Bonnot","year":"2021","journal-title":"Br. J. Surg."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10120-019-00978-0","article-title":"Peritoneal metastasis in gastric cancer: Results from the German database","volume":"23","author":"Rau","year":"2020","journal-title":"Gastric Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S1040","DOI":"10.1016\/j.annonc.2021.08.1485","article-title":"1376O The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery (CRS) in gastric cancer (GC) with synchronous peritoneal metastasis (PM): A randomized multicentre phase III trial (GASTRIPEC-I-trial)","volume":"32","author":"Rau","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer","volume":"47","author":"Alyami","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1245\/s10434-015-5081-3","article-title":"Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?","volume":"23","author":"Chia","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00423-021-02137-5","article-title":"Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: Experience from a Western tertiary referral center","volume":"406","author":"Rosa","year":"2021","journal-title":"Langenbeck\u2019s Arch. Surg."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1245\/s10434-020-08739-5","article-title":"A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology","volume":"28","author":"Badgwell","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1159\/000516959","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy-Related Clinical Trials in the Treatment of Peritoneal Metastases","volume":"99","author":"Ukegjini","year":"2021","journal-title":"Oncology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"20180116","DOI":"10.1515\/pp-2018-0116","article-title":"PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: A randomized and multicenter phase II study","volume":"3","author":"Eveno","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"782890","DOI":"10.1155\/2014\/782890","article-title":"Colorectal cancer: Prevention and management of metastatic disease","volume":"2014","author":"Sugarbaker","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.amjsurg.2016.03.008","article-title":"Peritoneal carcinomatosis of colorectal cancer: Novel clinical and molecular outcomes","volume":"213","author":"Massalou","year":"2017","journal-title":"Am. J. Surg."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/DCR.0000000000000412","article-title":"Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer: A Population-Based Study","volume":"58","author":"Quere","year":"2015","journal-title":"Dis. Colon Rectum."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/annonc\/mdt591","article-title":"Metastatic pattern in colorectal cancer is strongly influenced by histological subtype","volume":"25","author":"Hugen","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4251\/wjgo.v6.i10.407","article-title":"Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: An overview","volume":"6","year":"2014","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/bjc.2014.419","article-title":"Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone","volume":"111","author":"Mirnezami","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ejso.2014.06.006","article-title":"Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin","volume":"40","author":"Elias","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1016\/j.ejso.2021.05.046","article-title":"Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases","volume":"47","author":"Ljunggren","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1245\/s10434-015-4387-5","article-title":"Extent of colorectal peritoneal carcinomatosis: Attempt to define a threshold above which HIPEC does not offer survival benefit: A comparative study","volume":"22","author":"Goere","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/SLA.0b013e31827e9289","article-title":"Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?","volume":"257","author":"Goere","year":"2013","journal-title":"Ann. Surg."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S1470-2045(21)00192-3","article-title":"Limitations of the PRODIGE 7 trial\u2014Authors\u2019 reply","volume":"22","author":"Quenet","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ejso.2016.03.014","article-title":"Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases","volume":"42","author":"Simkens","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/cncr.28729","article-title":"BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer","volume":"120","author":"Yaeger","year":"2014","journal-title":"Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41416-021-01620-6","article-title":"Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients","volume":"126","author":"Larsen","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/jnci\/djab001","article-title":"Site of Recurrence and Survival after Surgery for Colorectal Peritoneal Metastasis","volume":"113","author":"Breuer","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","article-title":"Mutations of RAS\/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin","volume":"268","author":"Schneider","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Krebsgesellschaft, D. (2019). S3-Leitlinie Kolorektales Karzinom, Langversion 2.1, Leitlinienprogramm Onkologie.","DOI":"10.1055\/a-0809-8972"},{"key":"ref_107","unstructured":"The National Institute for Health and Care Excellence (2020). Colorectal cancer. NICE Guideline, The National Institute for Health and Care Excellence."},{"key":"ref_108","unstructured":"National Comprehensive Cancer Network (2021). Colon Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), NCCN."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e621","DOI":"10.3747\/co.27.6919","article-title":"Canadian guidelines on the management of colorectal peritoneal metastases","volume":"27","author":"Dube","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Kamada, Y., Hida, K., Yonemura, Y., Sugarbaker, P.H., Ghabra, S., Ishihara, S., Nagata, H., Murono, K., Goi, T., and Katayama, K. (2021). The Characteristics of 206 Long-Term Survivors with Peritoneal Metastases from Colorectal Cancer Treated with Curative Intent Surgery: A Multi-Center Cohort from PSOGI. Cancers, 13.","DOI":"10.3390\/cancers13122964"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clcc.2020.06.010","article-title":"Patient Selection for Hyperthermic Intraperitoneal Chemotherapy in Patients with Colorectal Cancer: Consensus on Decision Making among International Experts","volume":"19","author":"Steffen","year":"2020","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","article-title":"Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis","volume":"254","author":"Quenet","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1245\/ASO.2004.08.014","article-title":"Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: Location, treatment, and outcome","volume":"11","author":"Verwaal","year":"2004","journal-title":"Ann. Surg. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ejso.2015.05.018","article-title":"Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review","volume":"41","author":"Nienhuijs","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jso.25277","article-title":"Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience","volume":"119","author":"Alzahrani","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/bjs.8908","article-title":"Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis","volume":"100","author":"Iversen","year":"2013","journal-title":"Br. J. Surg."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.clcc.2019.06.002","article-title":"Diagnostic Nodes of Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Among Colorectal Cancer Patients: A Swiss National Multicenter Survey","volume":"18","author":"Steffen","year":"2019","journal-title":"Clin. Colorectal Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e044811","DOI":"10.1136\/bmjopen-2020-044811","article-title":"First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: Protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II)","volume":"11","author":"Lurvink","year":"2021","journal-title":"BMJ Open"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ejso.2016.09.008","article-title":"Best practice for perioperative management of patients with cytoreductive surgery and HIPEC","volume":"43","author":"Raspe","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejso.2015.08.162","article-title":"Cytoreduction and hyperthermic intraperitoneal chemotherapy: The learning curve reassessed","volume":"42","author":"Kuijpers","year":"2016","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00268-014-2801-y","article-title":"Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy","volume":"39","author":"Kuijpers","year":"2015","journal-title":"World J. Surg."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1245\/s10434-013-3145-9","article-title":"Cytoreduction and HIPEC in the Netherlands: Nationwide long-term outcome following the Dutch protocol","volume":"20","author":"Kuijpers","year":"2013","journal-title":"Ann. Surg. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/17\/4275\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:21:33Z","timestamp":1760142093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/17\/4275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":123,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["cancers14174275"],"URL":"https:\/\/doi.org\/10.3390\/cancers14174275","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}